Emory University’s Blueprint Medicines BPMC Stock Holding History

Emory University’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-27,551	Closed	-$2.6M	–	26
2019 Q2	$2.6M	Buy	+27,551	New	+$2.27M	1.83%	9
2018 Q3	–	Sell	-33,101	Closed	-$2.1M	–	47
2018 Q2	$2.1M	Buy	33,101 +938	+3%	+$74.6K	1.39%	38
2018 Q1	$2.95M	Buy	+32,163	New	+$2.77M	2.11%	6

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Emory University's BPMC Position: Q3 2019 in Review

Emory University sold out of Blueprint Medicines (BPMC) in Q3 2019, closing a stake of 27,551 shares — an estimated $2.6M sold.

Emory University first reported a position in BPMC in Q1 2018 and held it in 3 quarters. The position peaked at $2.95M in Q1 2018. 220 funds tracked by Wall St. Rank hold BPMC as of Q3 2019.

Emory University reported no remaining Blueprint Medicines position as of Q3 2019 after selling out during the quarter.
Emory University sold 27,551 Blueprint Medicines shares in Q3 2019, an estimated $2.6M.
Emory University first reported a position in Blueprint Medicines in Q1 2018 and held it in 3 quarters.
Emory University's Blueprint Medicines position peaked at $2.95M in Q1 2018.
220 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2019.

Based on Emory University's 13F filing for Q3 2019, filed 14 Nov 2019.